Download FREE Report Sample
Download Free sampleMPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
Mucopolysaccharidosis Treatment Market contains market size and forecasts of Mucopolysaccharidosis Treatment in Global, including the following market information:
Global Mucopolysaccharidosis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Mucopolysaccharidosis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravenous Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Mucopolysaccharidosis Treatment include Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Mucopolysaccharidosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mucopolysaccharidosis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Mucopolysaccharidosis Treatment Market Segment Percentages, by Type, 2021 (%)
Intravenous
Intracerebroventricular (ICV)
Global Mucopolysaccharidosis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Mucopolysaccharidosis Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Other
Global Mucopolysaccharidosis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Mucopolysaccharidosis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mucopolysaccharidosis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Mucopolysaccharidosis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen
REGENXBIO Inc.
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics Inc.
Ultragenyx Pharmaceutical
Genzyme Corporation
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
